Vol 23, No 1 (2020)
Clinical vignette
Published online: 2020-01-31

open access

Page views 679
Article views/downloads 563
Get Citation

Connect on Social Media

Connect on Social Media

99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair

Sara Shakeri1, Parinaz Jahanpanah1, Ghasemali Divband, Toktam Massoudi, Kamran Aryana1
DOI: 10.5603/NMR.2020.0011
Pubmed: 32779178
Nucl. Med. Rev 2020;23(1):49-50.

Abstract

Brain metastases of PTC are rare and occur in 0.1-5% of the patients, especially in the poorly differentiated types that usually fail to concentrate iodine. We present a rare case of PTC with probable brain metastasis in a 58-year-old woman with a history of poorly differentiated PTC that showed elevated Tg levels and no metastasis was detected in the whole-body iodine scan, despite the positive 99m Tc-octreotide scintigraphy. This imaging modality could be helpful as a diagnostic guide for radionuclide therapy with labeled somatostatin analogs in cases of thyroid carcinoma with elevated Tg levels and negative whole-body iodine scan.

Article available in PDF format

View PDF Download PDF file

References

  1. Tsuda K, Tsurushima H, Takano S, et al. Brain metastasis from papillary thyroid carcinomas. Mol Clin Oncol. 2013; 1(5): 817–819.
  2. Lowe VJ, Mullan BP, Hay ID, et al. 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med. 2003; 44(9): 1402–1406.
  3. Zhang H, Zeng L, Liang C, et al. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol. 2012; 42(11): 1086–1090.
  4. Khan S, Sharibi A, Neff R, et al. Metastatic Hürthle cell carcinoma: a unique case report and review of the literature. Endocr Pract. 2005; 11(4): 285–289.
  5. Pryma DA, Schöder H, Gönen M, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006; 47(8): 1260–1266.
  6. Shinto AS, Kamaleshwaran KK, Mallia M, et al. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World J Nucl Med. 2015; 14(2): 101–108.
  7. Haslinghuis LM, Krenning EP, De Herder WW, et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001; 24(6): 415–422.
  8. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996; 81(7): 2541–2544.